NCT00725712 - Study of GSK1363089 in Metastatic Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 1, 2009

Study Completion Date

November 30, 2009

Conditions

Neoplasms, Gastrointestinal Tract

Interventions

DRUG

GSK1363089 (formerly XL880)

c-MET tyrosine kinase inhibitor

Trial Locations (17)

10016

GSK Investigational Site, New York

10021

GSK Investigational Site, New York

20007

GSK Investigational Site, Washington D.C.

27710

GSK Investigational Site, Durham

30309

GSK Investigational Site, Atlanta

35294

GSK Investigational Site, Birmingham

48201

GSK Investigational Site, Detroit

53792

GSK Investigational Site, Madison

59101

GSK Investigational Site, Billings

60637

GSK Investigational Site, Chicago

78705

GSK Investigational Site, Austin

85258

GSK Investigational Site, Scottsdale

87131

GSK Investigational Site, Albuquerque

90024

GSK Investigational Site, Los Angeles

94305

GSK Investigational Site, Stanford

97239

GSK Investigational Site, Portland

02114

GSK Investigational Site, Boston